Wednesday, July 16, 2014 9:53:17 AM
Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway
CNN Airs Story Showcasing Capricor's ALLSTAR Clinical Trial
GlobeNewswire Capricor Therapeutics
1 hour ago
LOS ANGELES, July 16, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today encouraging analysis of the completion of its MRI data at the six-month time point from Capricor's Phase I ALLSTAR trial.
"We are pleased to announce this additional milestone as we show continued progress and remain on track with our clinical timeline," said Capricor CEO, Linda Marban, Ph.D. "We are encouraged with this Phase I six-month data in that there are indications of both myocardial regeneration as well as possible functional improvements."
MRI data collected on the patients in the open-label dose-escalation study of the allogeneic CDC product (CAP-1002) revealed that those patients who would be included in the Phase II clinical study, by virtue of dose and tissue type compatibility, exhibited measurable improvements in ejection fraction, a global measure of the heart's pumping ability. Ejection fraction improved from an average of 38.9% at baseline to 44.1% at six-month follow-up. Measurements of infarct (scar) size, viable mass, and regional function also showed quantifiable improvements. Phase I of the ALLSTAR trial was funded in part by a grant received from the NIH. The company has previously announced that the Data Safety Monitoring Board found no serious safety signals and advised that the Phase II portion of the study be initiated.
Capricor is now enrolling ALLSTAR Phase II, a clinical trial evaluating the effectiveness of CAP-1002 in reducing infarct size in patients who have suffered a myocardial infarction (heart attack) more than 30 days and less than 12 months prior to treatment with CAP-1002. The estimated 300-patient, double-blind, randomized, placebo-controlled trial is powered to detect a reduction in infarct size as measured by MRI. The Phase II trial is funded in part through the support of the California Institute for Regenerative Medicine (CIRM) through a loan award for approximately $19.8 million. Earlier this year, Capricor announced that Janssen Biotech, Inc., a wholly-owned subsidiary of Johnson & Johnson had entered into an exclusive option to license CAP-1002 which can be exercised anytime until 60 days after the six-month ALLSTAR Phase II data is available.
"We are optimistic, but given that this data represents a small sample with no concurrent control group, we are interpreting it with caution and looking forward to the results of the Phase II ALLSTAR study," continued Dr. Marban. "With funding from CIRM and our Collaboration Agreement and Exclusive License Option with Janssen Biotech, we are excited as we continue on our path towards commercialization with our CDC product."
CNN aired a story during Sanjay Gupta's program this past weekend discussing Capricor's ALLSTAR clinical trial, which further highlights the importance of our ongoing trial. For the full story click here: http://www.cnn.com/2014/07/11/health/stem-cells-heart-damage/index.html?hpt=he_c1
About Capricor Therapeutics
Capricor Therapeutics, Inc. (CAPR), a publicly-traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat cardiovascular diseases. Capricor Therapeutics has two leading product candidates: CAP-1002 and Cenderitide. Capricor Therapeutics was formed through the November 2013 merger between Capricor, Inc., a privately-held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company looking to develop innovative products for the treatment of cardiovascular diseases. For additional information, please visit www.capricor.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014, our Form 10-Q for the quarter ended March 31, 2014, as filed with the Securities and Exchange Commission on May 15, 2014, and in our Amendment No. 1 to Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on May 23, 2014. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.
For more information or to schedule an interview with Dr. Marban, please contact:
Capricor Therapeutics, Inc.
AJ Bergmann, Vice President of Finance
+1-310-358-3200
abergmann@capricor.com
Investor Contact
ProActive Capital Group
Kirin M. Smith, Chief Operating Officer
Ksmith@ProActiveCapital.com
646.863.6519
www.proactivecapital.com
Recent CAPR News
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 09/24/2024 08:03:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2024 08:01:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 08:01:08 PM
- Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy • GlobeNewswire Inc. • 09/24/2024 12:00:00 PM
- Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024 • GlobeNewswire Inc. • 09/23/2024 01:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/17/2024 01:15:10 PM
- Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 09/17/2024 01:15:00 PM
- Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences • GlobeNewswire Inc. • 09/06/2024 12:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:02:26 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/23/2024 08:01:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 01:00:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:00:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:06:46 PM
- Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/07/2024 08:05:00 PM
- Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7 • GlobeNewswire Inc. • 07/31/2024 01:00:00 PM
- Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes • GlobeNewswire Inc. • 07/01/2024 01:00:00 PM
- Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 06/28/2024 01:00:00 PM
- Capricor Therapeutics • GlobeNewswire Inc. • 06/25/2024 02:30:57 PM
- Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 06/25/2024 12:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/14/2024 08:31:21 PM
- Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway • GlobeNewswire Inc. • 06/11/2024 01:25:00 PM
- Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 06/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:05:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:00:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 01:00:46 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM